According to the report, the global acute graft versus host disease treatment market was valued at US$ 263 Mn in 2020 and is projected to expand at a CAGR of 8.6% from 2021 to 2031.
Acute Graft Versus Host Disease (GvHD) Treatment Market: Introduction
According to the report, the global acute graft versus host disease (GvHD) treatment market was valued at US$ 263 Mn in 2020 and is projected to expand at a CAGR of 8.6% from 2021 to 2031. The rise in focus on introducing novel effective therapeutics to address the unmet medical needs is anticipated to drive the global acute graft versus host disease (GvHD) treatment market from 2021 to 2031. North America is expected to account for significant share of the global acute graft versus host disease (GvHD) treatment market during the forecast period. The growth of the acute graft versus host disease (GvHD) treatment market in the region can be attributed to the presence of key players and rise in access to health care due to well-established healthcare infrastructure.
The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031. Emerging approached for mesenchymal stem cells (MSCs) to treat acute graft versus host disease (GvHD) in Japan is projected to boost the growth of market in the region.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82607
Focus on Research & Development to Propel Market
The development of innovative and effective health products for humans has increased in the past few decades. Key players focus on introduction of new drugs in the market. The research-based pharmaceutical industry can play a critical role in restoring growth and ensuring future competitiveness in an advancing global economy. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market. For instance, in July 2021, Equillium, Inc. announced the completion of an end-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) for use of itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD).
Request for Analysis of COVID-19 Impact on Acute Graft Versus Host Disease [GvHD] Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82607
Corticosteroids to Dominate Global Market
In terms of drug class, the global acute graft versus host disease (GvHD) treatment market has been classified into corticosteroids, immunosuppressive agents, biological therapy, kinase inhibitors, monoclonal antibody, mesenchymal stem cell (MSC), and others. First-line use of corticosteroids in the treatment of GvHD is likely to boost the growth of segment.
Intravenous Segment to Expand at High Growth Rate
Based on route of administration, the global acute graft versus host disease (GvHD) treatment market has been categorized into oral, topical, and intravenous. Increase in usage and launch of new injectable drugs for treatment of acute graft versus host disease are projected to augment the segment during the forecast period.
Buy Acute Graft Versus Host Disease [GvHD] Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=82607<ype=S
Retail Pharmacies to Account for Major Share of Global Market
In terms of distribution channel, the global acute graft versus host disease (GvHD) treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The increase in the number of different doses and medications for the treatment of acute GvHD is anticipated to drive the retail pharmacies segment.
Top of Form
Ask for Discount :
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=82607
Competition Landscape of Acute Graft Versus Host Disease (GvHD) Treatment Market
The report provides profiles of leading players operating in the global acute graft versus host disease (GvHD) treatment market. These include Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd, Equillium, Inc., Cynata Therapeutics Limited, MaaT Pharma, Incyte Corporation, Xenikos B.V., Merck & Co. (OncoImmune, Inc.), medac GmbH, and CSL Limited.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453